SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR)
XNCR 14.37+5.0%Nov 5 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche10/28/2014 4:34:33 PM
1 Recommendation

Recommended By
fitzdad55

  Read Replies (1) of 136
 
Lots going on here today. First, they certainly have addressed Tuck's recent concern!

Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD)
Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014
Conference call today at 5:00 p.m. EDT


finance.yahoo.com

nature.com

(Ironic, the advertisement at the top of this page, my view, reads "Amgen is committed to the science of personalized medicine".)

(Handcuffs are off.)

And then there's this.....

Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy

finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext